TP53 and cancer: In families with clinical definitions of LFS/LFL, about 25 to 30% of p.R337H carriers remain apparently cancer-free over their lifetime (compared to a penetrance of over 90% in carriers of germline TP53 mutations occurring at "hotspot" codons).